Lu Hongxiang, Zhang Yuezhan
Department of Laboratory, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Lianyungang, 222000, Jiangsu, China.
Department of Geriatrics, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Lianyungang, 222000, Jiangsu, China.
Appl Biochem Biotechnol. 2025 Feb;197(2):1002-1009. doi: 10.1007/s12010-024-05070-7. Epub 2024 Sep 30.
The long non-coding RNA (LncRNA) SNHG14 has been investigated for its potential in acute ischemic stroke (AIS) and transient ischemic attack (TIA) diagnosis. Thirty-two healthy people, 85 patients with AIS, and 40 patients with TIA had their blood tested to determine SNHG14 mRNA transcript levels using quantitative real-time polymerase chain reaction (qRT-PCR). A stroke's severity was measured using the Stroke Severity Scale developed by the National Institutes of Health (NIHSS). After 30 days, individuals with AIS were evaluated for progress using a modified Rankin Scale (mRS). There was no significant difference in SNHG14 LncRNA levels between TIA patients and controls, despite the huge rise in AIS incidence (p > 0.05) (all p < 0.001). Compared to those who did well on the AIS test, those who performed poorly had substantially greater levels of SNHG14 LncRNA (mRS 0-1 points) (mRS 0-2). LncRNA SNHG14 had an AUC of 0.714 (80%, 61.18%) when used to identify AIS in TIA patients, and a comparable finding was seen when predicting a poor 30-day prognosis of AIS (73%, 66.67%). There are also graphical representations of the findings. Improvements in NIHSS and mRS scores were associated with increases in SNHG14 LncRNA mRNA levels in individuals diagnosed with AIS. It is critical that we focus entirely on this decision (all p < 0.05). Analysis of the long non-coding RNA known as SNHG14 in the patient's blood can be used to diagnose AIS, rule out TIA, forecast the intensity of the disease, and evaluate the prognosis. You can accomplish everything on that list simultaneously.
人们已经对长链非编码RNA（LncRNA）SNHG14在急性缺血性卒中（AIS）和短暂性脑缺血发作（TIA）诊断中的潜力进行了研究。对32名健康人、85名AIS患者和40名TIA患者进行血液检测，使用定量实时聚合酶链反应（qRT-PCR）来确定SNHG14 mRNA转录水平。使用美国国立卫生研究院（NIH）制定的卒中严重程度量表（NIHSS）来衡量卒中的严重程度。30天后，使用改良Rankin量表（mRS）对AIS患者的病情进展进行评估。尽管AIS发病率大幅上升，但TIA患者和对照组之间的SNHG14 LncRNA水平没有显著差异（p＞0.05）（所有p＜0.001）。与AIS检测结果良好的患者相比，检测结果不佳的患者（mRS 0 - 1分）（mRS 0 - 2）的SNHG14 LncRNA水平显著更高。LncRNA SNHG14用于识别TIA患者中的AIS时，曲线下面积（AUC）为0.714（80%，61.18%），在预测AIS患者30天预后不良时也有类似发现（73%，66.67%）。研究结果也有图表展示。在被诊断为AIS的个体中，NIHSS和mRS评分的改善与SNHG14 LncRNA mRNA水平的升高相关。我们完全专注于这一决定至关重要（所有p＜0.05）。分析患者血液中名为SNHG14的长链非编码RNA可用于诊断AIS、排除TIA、预测疾病严重程度以及评估预后。你可以同时完成该清单上的所有事项。
